缺鐵性貧血治療市場報告：2030 年趨勢、預測與競爭分析

缺鐵性貧血治療的趨勢與預測

預計到 2030 年，全球缺鐵性貧血治療市場將達到約 46 億美元，2024 年至 2030 年複合年成長率為 5.3%。該市場的主要促進因素是缺鐵性貧血的高發病率，特別是影響婦女和兒童，這是由於食品中鐵攝入不足和紅血球過度消耗所致，女性人口迅速增加，女性健康意識不斷增強； 。全球缺鐵性貧血治療市場的未來看起來充滿希望，醫院、診所和居家醫療市場都充滿機會。

缺鐵性貧血治療市場洞察

Lucintel 預測，由於接受重組促促血紅細胞生長素治療的患者和患有阻礙口服鐵吸收的慢性疾病的患者的高需求，腸外鐵劑治療將在整個預測期內保持最大的佔有率。

醫院將繼續成為該市場中最大的部分，因為它們有更好的能力來處理複雜的病例，並擁有管理患者所需的設施和人員。

由於醫療保健支出迅速增加、人口中缺鐵性貧血盛行率增加以及該地區主要市場參與者的存在，預計北美在整個預測期內仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球缺鐵性貧血治療市場預計將達到 46 億美元。

Q2.市場成長預測是多少：

A2. 2024年至2030年，全球缺鐵性貧血治療市場預計將以5.3%的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要促進因素是缺鐵性貧血的高發，由於食品中鐵攝入不足和紅血球過度減少，缺鐵性貧血尤其影響婦女和兒童；這是由於人們對缺鐵性貧血的認知迅速提高。

Q4.市場的主要細分市場是：

A4. 全球缺鐵性貧血治療市場前景廣闊，醫院、診所和居家醫療市場充滿機會。

Q5.市場的主要企業是：

A5.主要的缺鐵性貧血治療公司如下。

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計，由於接受重組促促血紅細胞生長素治療的患者以及患有阻礙口服鐵吸收的慢性疾病的患者的需求量很大，因此在整個預測期內，腸外鐵劑治療仍將是最大的部分。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於醫療保健成本迅速上升、人口中缺鐵性貧血的盛行率增加以及該地區主要市場參與者的存在，預計北美在整個預測期內仍將是最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球缺鐵性貧血治療市場：市場動態

• 簡介、背景、分類
• 供應鏈
• 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

• 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
• 全球缺鐵性貧血治療市場趨勢（2018-2023）與預測（2024-2030）
• 按治療方法的全球缺鐵性貧血治療市場
  • 口服鐵劑療法
  • 腸外鐵劑治療
  • 紅血球輸注
• 全球缺鐵性貧血治療市場（依最終用途）
  • 醫院
  • 診所
  • 居家醫療

第4章 2018-2030年區域市場趨勢及預測分析

• 全球缺鐵性貧血治療市場（按地區）
• 北美缺鐵性貧血治療市場
• 歐洲缺鐵性貧血治療市場
• 亞太地區缺鐵性貧血治療市場
• 其他地區缺鐵性貧血治療市場

第5章 競爭分析

• 產品系列分析
• 營運整合
• 波特五力分析

第6章 成長機會與策略分析

• 成長機會分析
  • 全球缺鐵性貧血治療市場成長機會（依治療方法）
  • 全球缺鐵性貧血治療市場成長機會（依最終用途）
  • 全球缺鐵性貧血治療市場按地區成長機會
• 全球缺鐵性貧血治療市場的新趨勢
• 戰略分析
  • 新產品開發
  • 擴大全球缺鐵性貧血治療市場的產能
  • 全球缺鐵性貧血治療市場的併購與合資企業
  • 認證和許可

第7章主要企業概況

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Iron Deficiency Anemia Therapy Trends and Forecast

The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets. The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030 with a CAGR of 5.3% from 2024 to 2030. The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

A more than 150-page report is developed to help in your business decisions.

Iron Deficiency Anemia Therapy by Segment

The study includes a forecast for the global iron deficiency anemia therapy by therapy type, end use, and region.

Iron Deficiency Anemia Therapy Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion

Iron Deficiency Anemia Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals
• Clinics
• Home Healthcare

Iron Deficiency Anemia Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Iron Deficiency Anemia Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies iron deficiency anemia therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the iron deficiency anemia therapy companies profiled in this report include-

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Iron Deficiency Anemia Therapy Market Insights

Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Within this market, hospital will remain the largest segment as it is equipped to handle complex cases and has necessary facilities and staffs to manage patients.

North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Features of the Global Iron Deficiency Anemia Therapy Market

Market Size Estimates: Iron deficiency anemia therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Iron deficiency anemia therapy market size by therapy type, end use, and region in terms of value ($B).

Regional Analysis: Iron deficiency anemia therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy types, end uses, and regions for the iron deficiency anemia therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the iron deficiency anemia therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the iron deficiency anemia therapy market size?

Answer: The global iron deficiency anemia therapy market is expected to reach an estimated $4.6 billion by 2030.

Q2. What is the growth forecast for iron deficiency anemia therapy market?

Answer: The global iron deficiency anemia therapy market is expected to grow with a CAGR of 5.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the iron deficiency anemia therapy market?

Answer: The major drivers for this market are high incidence of iron deficiency anemia is attributed to insufficient iron intake from food and excessive loss of red blood cells, particularly affecting women and children, surge in female population, and growing awareness towards women health.

Q4. What are the major segments for iron deficiency anemia therapy market?

Answer: The future of the global iron deficiency anemia therapy market looks promising with opportunities in the hospital, clinic, and home healthcare markets.

Q5. Who are the key iron deficiency anemia therapy market companies?

Answer: Some of the key iron deficiency anemia therapy companies are as follows:

• Abbvie
• Akebia Therapeutics
• AMAG Pharmaceuticals
• Daiichi Sankyo
• Pharmacosmos
• Sanofi
• Johnson and Johnson
• Fresenius
• ViforPharma
• Rockwell Medical

Q6. Which iron deficiency anemia therapy market segment will be the largest in future?

Answer: Lucintel forecasts that parenteral iron therapy will remain the largest segment over the forecast period due to high demand for patients receiving recombinant erythropoietin therapy or suffering from chronic diseases that hinder iron absorption through oral means.

Q7. In iron deficiency anemia therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to surge in healthcare spending, increasing prevalence of iron deficiency anemia among the population, and the presence of key market players in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the iron deficiency anemia therapy market by therapy type (oral iron therapy, parenteral iron therapy, and red blood cell transfusion), end use (hospitals, clinics, and home healthcare), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Iron Deficiency Anemia Therapy Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Iron Deficiency Anemia Therapy Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 3.3.1: Oral Iron Therapy
  • 3.3.2: Parenteral Iron Therapy
  • 3.3.3: Red Blood Cell Transfusion
• 3.4: Global Iron Deficiency Anemia Therapy Market by End Use
  • 3.4.1: Hospitals
  • 3.4.2: Clinics
  • 3.4.3: Home Healthcare

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Iron Deficiency Anemia Therapy Market by Region
• 4.2: North American Iron Deficiency Anemia Therapy Market
  • 4.2.2: North American Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.3: European Iron Deficiency Anemia Therapy Market
  • 4.3.1: European Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.3.2: European Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.4: APAC Iron Deficiency Anemia Therapy Market
  • 4.4.1: APAC Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.4.2: APAC Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare
• 4.5: ROW Iron Deficiency Anemia Therapy Market
  • 4.5.1: ROW Iron Deficiency Anemia Therapy Market by Therapy Type: Oral Iron Therapy, Parenteral Iron Therapy, and Red Blood Cell Transfusion
  • 4.5.2: ROW Iron Deficiency Anemia Therapy Market by End Use: Hospitals, Clinics, and Home Healthcare

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Therapy Type
  • 6.1.2: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by End Use
  • 6.1.3: Growth Opportunities for the Global Iron Deficiency Anemia Therapy Market by Region
• 6.2: Emerging Trends in the Global Iron Deficiency Anemia Therapy Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Iron Deficiency Anemia Therapy Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Iron Deficiency Anemia Therapy Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Abbvie
• 7.2: Akebia Therapeutics
• 7.3: AMAG Pharmaceuticals
• 7.4: Daiichi Sankyo
• 7.5: Pharmacosmos
• 7.6: Sanofi
• 7.7: Johnson and Johnson
• 7.8: Fresenius
• 7.9: ViforPharma
• 7.10: Rockwell Medical